Tonix Pharmaceuticals Holding Corp
TNXP17.070USD
-0.020-0.12%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
173.57MMarket Cap
LossP/E TTM
More Details of Tonix Pharmaceuticals Holding Corp Company
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Tonix Pharmaceuticals Holding Corp Info
Ticker SymbolTNXP
Company nameTonix Pharmaceuticals Holding Corp
IPO dateMar 29, 2010
CEOLederman (Seth)
Number of employees81
Security typeOrdinary Share
Fiscal year-endMar 29
Address26 Main Street, Suite 101
CityCHATHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code07928
Phone12129809155
Websitehttps://www.tonixpharma.com/
Ticker SymbolTNXP
IPO dateMar 29, 2010
CEOLederman (Seth)
Company Executives of Tonix Pharmaceuticals Holding Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Seth Lederman, M.D.
Dr. Seth Lederman, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
4.01K
+66666.67%
Mr. James Treco
Mr. James Treco
Lead Independent Director
Lead Independent Director
250.00
--
James R Hunter
James R Hunter
Director
Director
--
--
Ms. Margaret Smith Bell
Ms. Margaret Smith Bell
Independent Director
Independent Director
--
--
Dr. Adeoye Y. (Oye) Olukotun, M.D.
Dr. Adeoye Y. (Oye) Olukotun, M.D.
Independent Director
Independent Director
--
--
Maj. Gen. (Retd.) David L. Grange
Maj. Gen. (Retd.) David L. Grange
Independent Director
Independent Director
--
--
Dr. Gregory M. (Greg) Sullivan, M.D.
Dr. Gregory M. (Greg) Sullivan, M.D.
Chief Medical Officer, Secretary
Chief Medical Officer, Secretary
--
--
Ms. Carolyn E. Taylor
Ms. Carolyn E. Taylor
Independent Director
Independent Director
--
--
Mr. Bradley Saenger, CPA
Mr. Bradley Saenger, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Mr. Richard H. (Rich) Bagger, J.D.
Mr. Richard H. (Rich) Bagger, J.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Seth Lederman, M.D.
Dr. Seth Lederman, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
4.01K
+66666.67%
Mr. James Treco
Mr. James Treco
Lead Independent Director
Lead Independent Director
250.00
--
James R Hunter
James R Hunter
Director
Director
--
--
Ms. Margaret Smith Bell
Ms. Margaret Smith Bell
Independent Director
Independent Director
--
--
Dr. Adeoye Y. (Oye) Olukotun, M.D.
Dr. Adeoye Y. (Oye) Olukotun, M.D.
Independent Director
Independent Director
--
--
Maj. Gen. (Retd.) David L. Grange
Maj. Gen. (Retd.) David L. Grange
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Dec 5
Updated: Fri, Dec 5
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
5.38%
The Vanguard Group, Inc.
4.85%
Geode Capital Management, L.L.C.
1.71%
Northern Trust Investments, Inc.
1.41%
State Street Investment Management (US)
1.30%
Other
85.35%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
5.38%
The Vanguard Group, Inc.
4.85%
Geode Capital Management, L.L.C.
1.71%
Northern Trust Investments, Inc.
1.41%
State Street Investment Management (US)
1.30%
Other
85.35%
Shareholder Types
Shareholders
Proportion
Investment Advisor
12.93%
Investment Advisor/Hedge Fund
5.78%
Hedge Fund
1.21%
Bank and Trust
0.18%
Venture Capital
0.17%
Research Firm
0.13%
Pension Fund
0.09%
Individual Investor
0.06%
Insurance Company
0.02%
Other
79.43%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
128
1.83M
18.40%
+1.18M
2025Q2
95
774.96K
9.35%
+537.73K
2025Q1
83
504.61K
6.66%
+350.52K
2024Q4
74
174.78K
3.08%
+157.04K
2024Q3
66
28.22K
4.02%
+21.74K
2024Q2
71
6.96K
10.29%
+2.86K
2024Q1
83
4.49K
18.21%
-214.00
2023Q4
91
5.24K
28.61%
+3.88K
2023Q3
92
1.16K
20.89%
+669.00
2023Q2
108
326.00
10.09%
-171.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
386.46K
4.42%
+316.88K
+455.41%
Jun 30, 2025
The Vanguard Group, Inc.
164.73K
1.88%
+73.24K
+80.04%
Jun 30, 2025
Geode Capital Management, L.L.C.
175.21K
2%
+113.17K
+182.43%
Jun 30, 2025
Northern Trust Investments, Inc.
162.45K
1.85%
+149.38K
+1143.08%
Jun 30, 2025
State Street Investment Management (US)
123.26K
1.41%
+103.20K
+514.66%
Jun 30, 2025
Fidelity Management & Research Company LLC
12.75K
0.15%
+12.75K
--
Jun 30, 2025
UBS Financial Services, Inc.
11.33K
0.13%
+1.67K
+17.27%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Neuroscience and Healthcare ETF
0.23%
Vanguard US Momentum Factor ETF
0.08%
ALPS Medical Breakthroughs ETF
0.06%
iShares Micro-Cap ETF
0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
Avantis US Small Cap Equity ETF
0.01%
View more
iShares Neuroscience and Healthcare ETF
Proportion0.23%
Vanguard US Momentum Factor ETF
Proportion0.08%
ALPS Medical Breakthroughs ETF
Proportion0.06%
iShares Micro-Cap ETF
Proportion0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.02%
iShares Russell 2000 Value ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 03, 2025
Merger
100→1
Feb 03, 2025
Merger
100→1
Feb 03, 2025
Merger
100→1
Feb 03, 2025
Merger
100→1
Jun 06, 2024
Merger
32→1
Jun 06, 2024
Merger
32→1
Date
Type
Ratio
Feb 03, 2025
Merger
100→1
Feb 03, 2025
Merger
100→1
Feb 03, 2025
Merger
100→1
Feb 03, 2025
Merger
100→1
Jun 06, 2024
Merger
32→1
Jun 06, 2024
Merger
32→1
Jun 06, 2024
Merger
32→1
Jun 06, 2024
Merger
32→1
May 09, 2023
Merger
6.25→1
May 09, 2023
Merger
6.25→1
View more
FAQs
Who are the top five shareholders of Tonix Pharmaceuticals Holding Corp?
The top five shareholders of Tonix Pharmaceuticals Holding Corp are:
BlackRock Institutional Trust Company, N.A. holds 386.46K shares, accounting for 4.42% of the total shares.
The Vanguard Group, Inc. holds 164.73K shares, accounting for 1.88% of the total shares.
Geode Capital Management, L.L.C. holds 175.21K shares, accounting for 2.00% of the total shares.
Northern Trust Investments, Inc. holds 162.45K shares, accounting for 1.85% of the total shares.
State Street Investment Management (US) holds 123.26K shares, accounting for 1.41% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 386.46K shares, accounting for 4.42% of the total shares.
The Vanguard Group, Inc. holds 164.73K shares, accounting for 1.88% of the total shares.
Geode Capital Management, L.L.C. holds 175.21K shares, accounting for 2.00% of the total shares.
Northern Trust Investments, Inc. holds 162.45K shares, accounting for 1.85% of the total shares.
State Street Investment Management (US) holds 123.26K shares, accounting for 1.41% of the total shares.
What are the top three shareholder types of Tonix Pharmaceuticals Holding Corp?
The top three shareholder types of Tonix Pharmaceuticals Holding Corp are:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Geode Capital Management, L.L.C.
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Geode Capital Management, L.L.C.
How many institutions hold shares of Tonix Pharmaceuticals Holding Corp (TNXP)?
As of 2025Q3, 128 institutions hold shares of Tonix Pharmaceuticals Holding Corp, with a combined market value of approximately 1.83M, accounting for 18.40% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 9.05%.
What is the biggest source of revenue for Tonix Pharmaceuticals Holding Corp?
In --, the -- business generated the highest revenue for Tonix Pharmaceuticals Holding Corp, amounting to -- and accounting for --% of total revenue.
